CTAS vs RIGL · P/E 51, rev $11.26B vs P/E 9.1, rev $137.5M
Cintas Corporation (CTAS) versus Rigel Pharmaceuticals Inc (RIGL) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported RIGL revenue for 2026-06-30 was $137.5M. Net income was $25.9M. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Not investment advice. Open the CTAS and RIGL stock pages for the full models.
Not investment advice.